Perennial allergic conjunctivitis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1)Patients aged 55 years or older 2)Patients diagnosed as perennial allergic conjunctivitis in the both eyes. 3)Patients with moderate or severe ocular pruritus and switching medication after treated with olopatadine hydrochloride ophthalmic solution for not less than two weeks at the time of informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients given immunotherapy (hyposensitization therapy, modulated therapy). 2)Patients with ocular pruritus and hyperemia caused by a disease other than allergic conjunctivitis which will influence drug evaluation. 3)Patients with a history of atopic keratoconjunctivitis, spring catarrh, giant papillary conjunctivitis, corneal herpes, recurrent corneal erosion caused by the frequent occurrence of corneal injury or dry eye. 4)Patients with surgical history in the internal eye (including laser therapy) within 90 days prior to initiation of the clinical research. 5)Patients with possibility taking medicines (including adrenal cortex steroid, anti-allergic agent and immunosuppressive drugs) which affect the efficacy of study drug. However, the use of ophthalmic solutions of adrenal cortex steroid is admitted as needed if there is no improvement in symptoms. 6)Females who are or may be pregnant, or lactating 7)Patients with a history of hypersensitivity to study drug or test material. 8)Patients with severe complications (such as immediate hospitalized care is required) which are identified inappropriate for safety reason. 9)Patients who have any other reasons that causes the study doctor to deem a subject unsuitable for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement rate of pruritus | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in scores of subjective symptoms (at visits) Change in scores of objective findings (at visits) Change in scores of fluorescein corneal staining(at visits) | — |
Countries
Japan
Contacts
Inouye Eye Hospital Medical office